I-CoPE: A pilot study of structured supportive care delivery to people with newly diagnosed high-grade glioma and their carers
- PMID: 31385998
- PMCID: PMC6656299
- DOI: 10.1093/nop/npy010
I-CoPE: A pilot study of structured supportive care delivery to people with newly diagnosed high-grade glioma and their carers
Abstract
Background: There is limited evidence to guide best approaches to supportive care delivery to patients with high-grade glioma. I-CoPE (Information, Coordination, Preparation and Emotional) is a structured supportive care approach for people with newly diagnosed high-grade glioma and their family carers. Delivered by a cancer care coordinator, I-CoPE consists of (1) staged information, (2) regular screening for needs, (3) communication and coordination, and (4) family carer engagement. This pilot study tested acceptability and preliminary effectiveness of I-CoPE, delivered over 3 transitions in the illness course, for people newly diagnosed with high-grade glioma and their carers.
Methods: I-CoPE was delivered at the identified transition times (at diagnosis, following the diagnostic hospitalization, following radiotherapy), with associated data collection (enrollment, 2 weeks, 12 weeks). Outcomes of interest included: acceptability/feasibility (primary); quality of life; needs for support; disease-related information needs; and carer preparedness to care (secondary). Descriptive statistics were used to assess acceptability outcomes, while patient and carer outcomes were assessed using repeated measures ANOVA.
Results: Thirty-two patients (53% male, mean age 60) and 31 carers (42% male) participated. I-CoPE was highly acceptable: 86% of eligible patients enrolled, and of these 88% completed the study. Following I-CoPE patients and carers reported fewer information needs (P < .001), while carers reported fewer unmet supportive care needs (P < .01) and increased preparedness to care (P = .04). Quality of life did not significantly change.
Conclusion: A model of supportive care delivered based upon illness transitions is feasible, acceptable, and suggests preliminary efficacy in some areas. Formal randomized studies are now required.
Keywords: high-grade glioma; quality of life; supportive care.
Figures
References
-
- Stupp R, Mason WP, van den Bent MJ et al. ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. - PubMed
-
- Philip J, Collins A, Brand CA et al. Health care professionals’ perspectives of living and dying with primary malignant glioma: Implications for a unique cancer trajectory. Palliat Support Care. 2015;13(6):1519–1527. - PubMed
-
- Philip J, Collins A, Brand CA et al. “I’m just waiting…”: an exploration of the experience of living and dying with primary malignant glioma. Support Care Cancer. 2014;22(2):389–397. - PubMed
-
- Collins A, Lethborg C, Brand C et al. The challenges and suffering of caring for people with primary malignant glioma: qualitative perspectives on improving current supportive and palliative care practices. BMJ Support Palliat Care. 2014;4(1):68–76. - PubMed
-
- Moore G, Collins A, Brand C et al. Palliative and supportive care needs of patients with high-grade glioma and their carers: a systematic review of qualitative literature. Patient Educ Couns. 2013;91(2):141–153. - PubMed
